CVS Group (LSE:CVSG) has spent the past year moving its shares to the Main Market, resolving a lengthy competition inquiry and adding practices in Australia. How is the veterinary group using acquisitions and Capital returns to grow, and what do its full-year results reveal about where that growth is coming from?

A veterinary group in the UK and Australia

CVS Group runs veterinary practices, mainly for companion animals, in the UK and Australia, alongside related services such as laboratories, an online pharmacy and the Healthy Pet Club subscription plan. The company said it moved its listing from AIM to the Main Market of the London Stock Exchange on 29 January 2026 and joined the FTSE 250 by March 2026, arguing that the change gives access to deeper pools of capital and better trading liquidity.

Full-year results and the Australian expansion

On 24 September 2026, CVS reported results for the year to 30 June 2026. Revenue rose 5.9% to £712.8 million and like-for-like sales grew 2.1%, compared with 0.2% a year earlier. Adjusted EBITDA increased 5.1% to £141.5 million, a 19.9% margin, and adjusted profit before tax rose 7.6% to £84.9 million. Statutory profit before tax was £32.0 million, down 1.8%, while adjusted Earnings Per Share grew 6.9% to 85.6p. The final Dividend was raised to 9.0p from 8.5p, and a 30 September announcement set its payment date as 4 December 2026.

Australia is a growing part of the group. CVS said it now operates 57 practice sites across 35 practices there, up from 43 sites, and that Australian revenue reached £79.1 million, roughly 11% of the total. During the year it completed six practice acquisitions covering 14 sites for £43.3 million, and after the year end it bought two more businesses with four sites for A$9.3 million, with contracts exchanged on further deals. The chief executive described Australia as an area that "continues to perform well" and offers "significant opportunity".

Capital allocation and the CMA outcome

The company has been returning cash to shareholders while continuing to invest. It completed a £20 million buyback and has a further £50 million programme under way, alongside Capital Expenditure of £36.4 million, or about 5% of revenue. Net Debt was £199.6 million, representing Leverage of 1.63 times.

CVS said the Competition and Markets Authority published final remedies on 22 September 2026, concluding its market investigation into veterinary services. The group reported £5.1 million of related implementation costs, mainly joint rebranding of UK practices, and said price lists are already published on its websites. The company also launched an advanced Healthy Pet Club tier in July 2026 offering unlimited consultations. Membership of the scheme dipped to 508,000 from 519,000, although subscription revenue grew 3.5% to £95.5 million.

Risks to watch

UK like-for-like growth remains modest, and the CMA remedies may change how practices price and present services, with effects that will become clearer as they are implemented. Acquisition-led growth in Australia depends on finding suitable practices at sensible prices and on integrating them well, and currency movements affect reported results. The gap between adjusted and statutory profit is wide, and management succession is another factor, as chief executive Richard Fairman has announced plans to retire, although he has said he remains committed to the Leadership transition.

Conclusion

CVS Group is growing through steady organic gains in the UK, a buy-and-build strategy in Australia and a buyback funded alongside acquisitions, with leverage kept below two times EBITDA. The company said it expects FY27 to be in line with market expectations, and it cited an analyst consensus of £150.4 million adjusted EBITDA and 94.9p adjusted earnings per share. How UK practices adapt to the CMA remedies, and whether the Australian expansion maintains its pace, are likely to shape the next stage.